Fda accepts libtayo® (cemiplimab-rwlc) for priority review for advanced cervical cancer

Tarrytown, n.y., sept. 28, 2021 /prnewswire/ -- european union regulatory submission planned by end of 2021 regeneron pharmaceuticals, inc. (nasdaq: regn) today announced that the u.s. food and drug administration (fda) has accepted for priority review the supplemental biologics license application (sbla) for pd-1 inhibitor libtayo® (cemiplimab-rwlc) to treat patients with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy.
REGN Ratings Summary
REGN Quant Ranking